Royalty Pharma’s Strong Portfolio and Future Growth Potential Underpin Buy Rating

TD Cowen analyst Michael Nedelcovych reiterated a Buy rating on Royalty Pharma (RPRX – Research Report) today and set a price target of $42.00.

Michael Nedelcovych’s rating is based on several compelling factors. Royalty Pharma’s diverse portfolio was a focal point at TD Cowen’s recent Health Care Conference, where multiple products and pipeline candidates were discussed favorably. This positive sentiment, particularly from key opinion leaders, suggests strong future performance for the company’s assets.
Key products like Tysabri, Tremfya, and Trodelvy are expected to generate significant royalty receipts by 2030, contributing to the company’s financial health. Tysabri, for instance, is projected to maintain its market presence despite competition, while Tremfya and Trodelvy are anticipated to perform well in their respective therapeutic areas. These factors collectively underpin the Buy rating, reflecting confidence in Royalty Pharma’s long-term growth potential.